Urinary microalbumin as a marker for intermittent claudication

Pentoxifylline for intermittent claudication.

BACKGROUND Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in...

Buflomedil for intermittent claudication.

BACKGROUND Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined. This is an update of a Cochrane review first published in 2000, and previously upd...

Intermittent claudication

Peripheral arterial disease is a common health problem that globally affects over 200 million individuals, and intermittent claudication (IC) is the most common symptomatic presentation. The leg symptoms in IC are provoked by walking exercise and can be alleviated by medical intervention, exercise training and invasive vascular interventions (revascularization). The quality of evidence for inva...

Intermittent claudication; a clinical study.

Pentoxifylline for intermittent claudication. A critical review.

Pentoxifylline was first introduced in Germany twenty years ago. Today it is the best researched oral drug for intermittent claudication. A total of seventeen placebo-controlled trials could be retrieved from the world literature. The majority of these studies show that pentoxifylline will prolong the walking distance in a statistically significant way. Even though these trials are conducted wi...